Positive Results Of CollaGenex Pharmaceuticals, Inc.'s (CGPI) Phase III Clinical Study Evaluating Periostat As A Treatment For Rosacea Presented At Phoenix Dermatology Open Seminar
Reduction of Inflammatory Lesions in Periostat(R) Patients 76% Higher Than That of Control Group
NEWTOWN, Pa.--(BUSINESS WIRE)--March 22, 2004-- CollaGenex Pharmaceuticals, Inc. (Nasdaq:CGPI - News) today announced positive results of a Phase III double-blinded, placebo-controlled clinical study designed to evaluate the safety and efficacy of Periostat® (doxycycline hyclate tablets) 20 mg, for the treatment of rosacea. A presentation of these results was made yesterday by a principal investigator in the study, Diane M. Thiboutot, M.D., Professor of Dermatology, Pennsylvania State University Medical College, at the Skin Disease Education Foundation's Phoenix Dermatology Open Seminar.
In the clinical study, 134 patients were randomized to receive either Periostat tablets or placebo for 16 weeks. Inflammatory lesion counts, along with an assessment of erythema (redness) and overall clinical disease severity, were obtained at baseline, 3, 6, 12 and 16 weeks. |
